Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Camillo Porta(University of Pavia), Cinzia Canipari(University of Pavia), Mara De Amici(University of Pavia), Lucia Sacchi(University of Pavia), Ilaria Imarisio(University of Pavia), Chiara Paglino, Silvana Quaglini(University of Pavia)
Cited by 99
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275